tikky
27 Jul 2017
div bought in @4300 note dividend ?70 p due soon I guess
contrarianstyle
27 Jul 2017
AstraZeneca drug flop is bad, not terminal AstraZeneca drug flop is bad, not terminal12
3(The author is a Reuters Breakingviews columnist. The opinions expressed are his own.)John FoleyLONDON, July 27 (Reuters Breakingviews) – AstraZeneca investors knew the company was going over a cliff – but it's now doing so without a safety net. As much as $14 billion was wiped off the UK drugmaker's value after it said on Thursday that trials of an important cancer treatment failed to live up to high hopes. The benign prognosis is that one set of options is transformed into other, albeit less attractive, alternatives.Immunotherapy, which uses the body's own defences to fight tumours, was the big hope for offsetting AstraZeneca's "patent cliff" – the loss of earnings from patents running out on key drugs. The MYSTIC trial, though, seems no more effective at stopping lung cancer in certain patients than chemotherapy. Final data won't come in until next year, but the signs aren't good.Assume the drugs in question could have had $7 billion of revenue by 2022. On an operating profit margin of 35 percent, that would have generated $2.5 billion. Putting that on the company's current valuation multiple of 16 times and discounting it back five years would make it worth $24 billion in today's money. Thursday's fall suggests shareholders had assigned around a 60 percent chance to the drug taking off.The question is whether those lost earnings can be replaced. One option might be to cut costs, or scale back investment in immunotherapy, which has become highly competitive. The trouble is that Astra would be trying to plug a hole left by long-term potential with short-term savings. And that reckons without management upset. Chief Executive Pascal Soriot, who is highly paid, hasn't firmly ruled out the prospect of cutting his losses and moving to a rival.But investors need not lose faith. Astra has had positive indications for another lung cancer drug, Tagrisso. And there's always the possibility of a takeover from a rival such as Novartis or Pfizer . The latter tried and failed to buy Astra in 2014. The company would be a big mouthful at more than $70 billion, but given the weaker state of its drug portfolio – and of the UK government, which was once minded to shield it from buyers – a deal may be the next most exciting thing in the pipeline.
QuelFromage
27 Jul 2017
Re: AZN trades 4283 long add - oversold IMO, plenty to come eg overall survival for the Imfinzi/tremelimumab and as another poster said not all bad news today.QF
sound money
27 Jul 2017
Re: AZN trades CFD Long 4282 added.Sorry for those that have taken a hit, even Woody. Taken no pleasure in seeing investors suffer a hit.Glad I'm in Glaxo where the new CEO confirmed the dividend going forward and took action to improve FCF.M
soi
27 Jul 2017
Re: AZN trades 4302 long addsoi
Proverbs 26 vs 5
27 Jul 2017
Not Quite all doom and gloom. AZ's Tagrisso meets primary endpoint in trial A phase III FLAURA trial of AstraZeneca's Tagrisso showed it significantly improved progression-free survival. AstraZeneca said Tagrisso met the primary endpoint, demonstrating a statistically-significant and clinically-meaningful progression-free survival benefit compared to current 1st-line standard-of-care treatment (erlotinib or gefitinib) in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer Executive vice-president, global medicines development and chief medical officer Sean Bohen said: "The strong results from the FLAURA trial are very exciting news for patients with EGFR mutation-positive non-small cell lung cancer, providing physicians with a potential new first-line treatment option to improve outcomes in this disease. "We will now initiate discussions with global health authorities on the data and regulatory submissions." At 9:47am: (LON:AZN) AstraZeneca PLC share price was -803.75p at 4309.25p Story provided by StockMarketWire.com
soi
27 Jul 2017
Re: AZN trades 4295 long add.Consider it is oversold.Could be very wrong of course.ATBsoi
Proverbs 26 vs 5
27 Jul 2017
I think I'll wait for the bid. As Soriot has said, it makes them vulnerable.
soi
27 Jul 2017
AZN trades 4272 long add.soi
PrefInvestor1
27 Jul 2017
Yo-Yo Stock !! Hi All,Have held this in the past but never got the timing right. Something happens and boom its up 10-15% or as today down 15%. The other week it was rumours of the CEO leaving and then it recovered from that. Now it seems that one of their drugs has failed some test somewhere and BOOM down big again.Nightmare. Good luck to all holders (especially Mr Woodford who is probably a bit miffed this morning). Not that GSK is doing much better.........Good for traders I guess !!!ATBPref
axolotl
27 Jul 2017
antibiotics advice I blame the Radio 4 Today programme. They tell people it's ok not to finish a course of antibiotics and look what it's done to my shares. Never mind, investors will now be popping the antidepressants instead and that should push the shares back up again.
soi
27 Jul 2017
Re: Down 15% at 089 4320 long added.So now 4 positions.Apologies Jack Walsh, I should have started my own trade thread rather than add to yours.Trying to do too much.ATB & GLsoi
gamesinvestor
27 Jul 2017
Re: Down 15% at 089 """pure joss I sold all my AZN shares at the beginning of this week as part of an IHT planning exercise so managed to miss this disaster, otherwise I would be squealing like the chubby boy in Deliverance after his encounter with the mountain men.""LK - grab your banjo, I can join you in a dual - as I sold this pup a while back.[link] guy dancing in the background is Woody's dad.Games -- maybe I shouldn't have sold Diageo though --- grrrrrr
soi
27 Jul 2017
Re: Down 15% at 089 I had nothing in but entered 3 SB longs today4316 4302 4306.Maybe I will be wrong.Big 1 day fall.They do often get somewhat bought back.ATB & GLsoi
reader61
27 Jul 2017
Re: Down 15% at 089 Presumably a dividend suspension is likely?
